Resource Summary Report

Generated by dkNET on Aug 15, 2026

Phospho-Histone H2A.X (Ser139) (20E3) Rabbit mAb

RRID:AB_2118009
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 9718, RRID:AB_2118009)

Antibody Information

URL: http://antibodyregistry.org/AB_2118009

Proper Citation: (Cell Signaling Technology Cat# 9718, RRID:AB_2118009)

Target Antigen: Histone H2A.X, phospho (Ser139)

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-Bond, IHC-P, IF-IC, FC-FP
Consolidation: AB_10121789.
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Phospho-Histone H2A.X (Ser139) (20E3) Rabbit mAb

Description: This recombinant monoclonal targets Histone H2A.X, phospho (Ser139)

Target Organism: monkey, rat, mouse, human

Clone ID: clone 20E3

Antibody ID: AB_2118009

Vendor: Cell Signaling Technology

Catalog Number: 9718

Alternative Catalog Numbers: 9718S, 9718P

Record Creation Time: 20260522T070015+0000

Record Last Update: 20260615T044124+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for Phospho-Histone H2A.X (Ser139) (20E3) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 435 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Wu T, et al. (2026) SARM1 executes neuronal parthanatos and promotes excitotoxic cell death. Neuron.

Kaddatz H, et al. (2026) Loss of oligodendrocyte transcription factor 2 protein expression in metabolically stressed oligodendrocytes. Acta neuropathologica, 151(1).

Goodluck HA, et al. (2026) Glomerular hyperfiltration and enhanced sensitivity to kidney ischemia reperfusion with a blunted KIM-1 response in young male aging-accelerated SAMP8 mice. American journal of physiology. Renal physiology, 330(4), F483.

Li C, et al. (2026) ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing. bioRxiv : the preprint server for biology.

Xie Y, et al. (2026) Ultraviolet A plays a protective role in ultraviolet B-induced squamous cell carcinoma through c-Fos/XRCC4 axis. Carcinogenesis, 47(2).

Wang Q, et al. (2026) FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity. Molecular cell.

Avolio M, et al. (2026) The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer. Cancer discovery, 16(2), 270.

Guo L, et al. (2026) Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA-binding proteins with prion-like domains. Molecular cell, 86(1), 114.

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. Cell reports, 45(1), 116784.

Zhang M, et al. (2026) Lamin A/C safeguards replication initiation by orchestrating chromatin accessibility and PCNA recruitment. Cell reports, 45(3), 117075.

Young TM, et al. (2026) CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. Cancers, 18(5).

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. Cancer research, 86(11), 2660.

Pakarinen E, et al. (2026) High-fat diet feeding induces organ-specific vascular remodeling with distinct temporal dynamics in male mice. Communications biology, 9(1).

Pribyl LJ, et al. (2026) Persistent interferon signaling and clonal expansion mark early events in DNA methylation damage-induced liver cancer. NAR cancer, 8(2), zcag014.

Nishinaka T, et al. (2026) IL-4/IL-13 signaling suppresses ABT-263-induced apoptosis in senescent human fibroblasts. International immunopharmacology, 184, 116939.

Zhou T, et al. (2026) Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(40), e21541.

Ishikawa KI, et al. (2026) Suppression of ATM kinase signaling accelerates cellular senescence. Stem cell reports, 21(7), 102956.

Ballarò R, et al. (2026) Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic Cancer. Cancer research.

Luo YN, et al. (2026) Tracking mobilization uncovers an evolutionarily conserved mechanism in suppressing mobile genetic elements. Molecular cell, 86(12), 2263.

Wang L, et al. (2026) ACSS2 is required for colorectal cancer progression and a druggable target for colorectal cancer treatment. iScience, 29(8), 116860.